Effect of the short –term thyrotropin increase after administration of Recombinant Human Thyrotropin on T lymphocyte cytokine production pattern and bone metabolism in healthy subjects
- Conditions
- This is a healthy volunteers trial. Thyrogen is used in patients with thyroid cancer.
- Registration Number
- EUCTR2006-004980-79-AT
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Men and women without evidence of thyroid disease. Age between 20-45.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Prior or present history of thyroid disease. Pregnancy or nursing. Significant cardiac, renal, pulmonary or hepatic disease. Recent surgery or trauma. Malnutrition. Ingestion of medications known to affect the thyroid function. Alcohol or drug dependence. Previous administration of rhTSH.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The main objective of the trial is the effect of recombinant human thyrotropin in bone metabolism and its correlation to the potential changes in the T-lymphocyte cytokine production pattern in healthy volunteers.;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method